Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.

Antzeko izenburuak

• Potential benefits of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and Type 2 diabetes? Results from the WELCOME study
  nork: Scorletti, E, et al.
  Argitaratua: (2014)
• Whole-body and hepatic dietary fatty acid oxidation is related to postprandial insulin concentrations in people with non-alcoholic fatty liver disease with varying degrees of insulin resistance
  nork: Hodson, L, et al.
  Argitaratua: (2013)
• Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
  nork: Hodson, L, et al.
  Argitaratua: (2017)
• Distinguishing Health Benefits of Eicosapentaenoic and Docosahexaenoic Acids
  nork: Fraser D. Russell, et al.
  Argitaratua: (2012-11-01)
• Meta-Analysis of Contemporary Trials of Omega-3 Fatty Acids Containing Both Eicosapentaenoic and Docosahexaenoic Acids
  nork: Safi U. Khan, MD, MS, et al.
  Argitaratua: (2021-09-01)